Read Why Did Credit Suisse Raise Price Target On Kura Oncology
Credit Suisse has raised the price target on Kura Oncology Inc (NASDAQ:KURA) to $29 from $27. The analysts say that evidence of an…
HC Wainwright Downgrades Humanigen On Disappointing COVID-19 Study – What’s Next
HC Wainwright downgraded Humanigen Inc (NASDAQ:HGEN) to Neutral from Buy and removed the price target based on the removal of COVID-19…
Amgen Touts Early Lumakras Combo Data In KRAS Cancer Settings
BMO Capital Markets says that while Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) + PD1i data was delayed to the August 7 presentation, it did get data on the Lumakras + SHP2 inhibitor combination.
Mizuho On Atara Biotherapeutics – Distinguish Between Small Numbers And Science Failure
Atara Biotherapeutics Inc (NASDAQ:ATRA) issued its anticipated interim analysis communication for its ATA188 Phase 2 progressive multiple sclerosis trial. Shares slumped…
Sanofi Offloads 17 Products To Neuraxpharm
Sanofi SA (NASDAQ: SNY) has entered a deal to hand over 17 products to central nervous system (CNS) specialist Neuraxpharm for an undisclosed sum.
HUTCHMED Highlights SAVANNAH Trial Data Of Savolitinib Combo In Lung Cancer Setting
HUTCHMED (China) Limited (NASDAQ:HCM) announced the first presentation of results from the ongoing SAVANNAH Phase 2 trial at the upcoming World…
Merck Makes $290M Bet On Prostate Cancer Candidate
Merck & Co Inc (NASDAQ:MRK) and Orion Corporation announced a global development and commercialization agreement for Orion’s ODM-208 and other drugs targeting cytochrome…
Apollo Endosurgery’s New Obesity Endoscopic Systems Receive FDA Nod
Apollo Endosurgery Inc (NASDAQ:APEN) announced the marketing authorization of the Apollo ESG, Apollo ESG Sx, Apollo REVISE, and Apollo REVISE Sx…
COSELA (Trilaciclib Hydrochloride For Injection) Now Approved In China To Decrease The Incidence Of Chemotherapy-Induced Myelosuppression In Patients With Extensive-Stage Small Cell Lung Cancer
COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
RESEARCH
ABVC Biopharma Provides Enrolment Update In Mid-Stage Attention Deficit Disorder Study
ABVC Biopharma (NASDAQ: ABVC) provided an update on the enrollment progress in the Phase II Part II clinical study of its ADHD candidate (ABV-1505).